MedTrace Logo

Clinical Trial to Evaluate the Long-term Safety of Udenafil in Patient With PAH

NCT02304198 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 59

Last updated 2016-04-18

No results posted yet for this study

Summary

This study evaluates the long-term safety of Udenafil in Patient with Pulmonary Arterial Hypertension(PAH). All the patients will receive Udenafil for 1-year(48-weeks).

Conditions

Interventions

DRUG

Udenafil

Udenafil 50mg tablet

Sponsors & Collaborators

  • Dong-A ST Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Duk-Kyung Kim, M.D., Ph.D. · Samsung Medical Center

  • Sung-A Jang, M.D., Ph.D. · Samsung Medical Center

  • Jun-Bin Park, M.D., Ph.D. · Seoul National University Hospital

  • Hyung-Kwan Kim, M.D., Ph.D. · Seoul National University Hospital

  • Hyuk-Jae Jang, M.D., Ph.D. · Severance Hospital

  • Hae-Ok Jung, M.D., Ph.D. · Seoul St. Mary's Hospital

  • Jung-Hyun Choi, M.D., Ph.D. · Pusan National University Hospital

  • Jae-Seung Lee, M.D., Ph.D. · Asan Medical Center

  • Kye-Hun Kim, M.D., Ph.D. · Chonnam National University Hospital

  • Jin-Ok Jeong, M.D., Ph.D. · Chungnam National University Hospital

  • Sang-Yeub Lee, M.D., Ph.D. · Chungbuk National University Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-04-30
Primary Completion
2016-02-29
Completion
2016-02-29

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02304198 on ClinicalTrials.gov